title: Drug discovery for hyperuricemia.
abstract: Hyperuricemia is associated with an increased risk of developing gout. This increases with the degree and duration of hyperuricemia. Gout can be managed by dietary modification and pharmacologic urate-lowering therapies. The recent identification of the renal apical urate/anion exchanger URAT1 (SLC22A12) and several membrane proteins relevant to the transport of urate play an important role in gaining a better understanding of the mode of action of many drugs used to treat gout. As described in this review, therapeutics designed to modify URAT1 transport activities might be useful in treating pathologies associated with hyperuricemia such as gout and urolithiasis. Continuing studies into the urate transportsome hold promise for the development of new, more effective therapeutics for hyperuricemia.
authors.affiliation: Kyorin University School of Medicine, Department of Pharmacology and Toxicology, 6-20-2, Shinkawa, Mitaka-shi, Tokyo 181-8611, Japan +81 422 47 5511 (ext 3692) ; +81 422 79 1321 ; anzai@kyorin-u.ac.jp.
authors.forename: Naohiko
authors.initials: N
authors.lastname: Anzai
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Endou